TY - JOUR
T1 - Effects of attention bias modification for anxiety
T2 - Neurophysiological indices and moderation by symptom severity
AU - Dennis Tiwary, Tracy A.
AU - Cho, Hyein
AU - Myruski, Sarah
N1 - Publisher Copyright:
© 2023 International Federation of Clinical Neurophysiology
PY - 2023/3
Y1 - 2023/3
N2 - Objective: Attention bias modification (ABM) aims to decrease anxiety symptom severity through the reduction of threat-related attention bias (AB). Individual differences in treatment response and poor measurement reliability of AB have called its clinical promise into question. The current study examined whether individual differences in anxiety severity at baseline moderated treatment response, and employed both behavioral and neurophysiological metrics of AB. Methods: Participants (N = 99) were randomly assigned to four weeks of ABM or placebo control training (PT). Self-reported anxiety symptom severity, and AB metrics and ERPs generated during the dot probe task were collected at baseline (Time 1), one-week post-intervention (Time 5), and at a three-month follow-up (Time 6). Results: ABM, relative to PT, reduced ERPs indexing attention discrimination (N170) and increased ERPs indexing salience tracking (P3). Increases in P3 were associated with ABM-related reductions in anxiety. Anxiety severity was reduced following ABM, but only among those with higher baseline anxiety symptom severity. Conclusions: ABM effectively reduced symptom severity among those with higher levels of anxiety, and modulated neurophysiological indices of AB. Significance: Results provide evidence for attention-relevant ERPs as outcomes of ABM treatment responsivity and suggest that ABM may be most beneficial for those with more severe anxiety symptoms.
AB - Objective: Attention bias modification (ABM) aims to decrease anxiety symptom severity through the reduction of threat-related attention bias (AB). Individual differences in treatment response and poor measurement reliability of AB have called its clinical promise into question. The current study examined whether individual differences in anxiety severity at baseline moderated treatment response, and employed both behavioral and neurophysiological metrics of AB. Methods: Participants (N = 99) were randomly assigned to four weeks of ABM or placebo control training (PT). Self-reported anxiety symptom severity, and AB metrics and ERPs generated during the dot probe task were collected at baseline (Time 1), one-week post-intervention (Time 5), and at a three-month follow-up (Time 6). Results: ABM, relative to PT, reduced ERPs indexing attention discrimination (N170) and increased ERPs indexing salience tracking (P3). Increases in P3 were associated with ABM-related reductions in anxiety. Anxiety severity was reduced following ABM, but only among those with higher baseline anxiety symptom severity. Conclusions: ABM effectively reduced symptom severity among those with higher levels of anxiety, and modulated neurophysiological indices of AB. Significance: Results provide evidence for attention-relevant ERPs as outcomes of ABM treatment responsivity and suggest that ABM may be most beneficial for those with more severe anxiety symptoms.
UR - http://www.scopus.com/inward/record.url?scp=85146172834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146172834&partnerID=8YFLogxK
U2 - 10.1016/j.clinph.2022.12.010
DO - 10.1016/j.clinph.2022.12.010
M3 - Article
C2 - 36642007
AN - SCOPUS:85146172834
SN - 1388-2457
VL - 147
SP - 45
EP - 57
JO - Clinical Neurophysiology
JF - Clinical Neurophysiology
ER -